What Personal Importation of a Medication Is, and Is Not

Answer first: the default is that it is not allowed

FDA's page on personal importation states the general position without hedging. In most circumstances, it is illegal for individuals to import drugs or devices into the United States for personal use, because these products purchased from other countries often have not been approved by FDA for use and sale here.

The next sentence closes the gap people usually reach for. If a drug is approved for use in another country but is an unapproved new drug in the United States, it is illegal to import.

Approval elsewhere is therefore not a defense. The question is whether the specific product, as labeled and marketed, is approved in the United States — not whether a regulator somewhere thought well of the molecule.

The agency then states its recommendation in one line: obtain medicines only from legal sources in the United States.

What the term actually means

The definition is narrower than the everyday use of the phrase. FDA defines a personal importation as a product not for further sale or distribution into U.S. commerce.

That single condition does a great deal of work. A shipment that appears intended for commercial distribution is not a personal importation at all, whatever the paperwork calls it. Appearing to be intended for commercial distribution is also one of the agency's listed grounds for refusing an entry.

The page points to the Regulatory Procedures Manual, Chapter 9-2, "Coverage of Personal Importations", as the underlying document.

It is worth being precise about what kind of document that is. A procedures manual tells agency staff how to exercise discretion. It is not a regulation that confers a right on an importer.

The statute underneath, and the two carve-outs it names

The reimportation provision of federal food and drug law is short and blunt. No drug subject to the prescription-drug provision, and none composed wholly or partly of insulin, that is manufactured in a State and exported, may be imported unless the importer is the manufacturer. Two exceptions are named on the face of it: one adjacent paragraph, and section 384.

That is the sentence people run into when they hear that an American drug sold abroad cannot simply be bought back. The manufacturer is the only party that may bring it home, subject to the two named exceptions.

A second subparagraph handles drugs made outside the United States. No prescription drug manufactured outside the United States may be imported for commercial use unless two things are true. The manufacturer has authorized it to be marketed here, and has caused it to be labeled to be marketed here. Two exceptions apply: a drug on the shortage list where the Secretary authorizes it, and importation under section 384.

The adjacent paragraph is narrow. The Secretary may authorize importation otherwise prohibited if the drug is required for emergency medical care.

Section 384 is a separate statutory route with its own machinery, and it is named here only because the reimportation provision names it.

The conditions FDA lists for a more permissive decision

This is the part that gets quoted secondhand and garbled, so here it is as the page frames it. FDA says that in allowing the importation of medications for personal use, its personnel may consider a more permissive decision in certain situations.

Read the verb. Personnel may consider. That is a description of how discretion is exercised, not a rule that entitles anyone to anything.

The first situation is simple: the product is not for treatment of a serious condition and there is no known significant health risk.

The second is for products treating a serious condition, which is where prescription drug products sit, and it carries five conditions rather than one. The product is for a serious condition for which effective treatment may not be available domestically, either through commercial or clinical means. There is no known commercialization or promotion of the product to persons residing in the United States. The product does not represent an unreasonable risk. The consumer affirms in writing that the product is for personal use. And the quantity is generally not more than a three month supply.

That last condition has a further requirement attached to it. Either give the name and address of a doctor licensed in the United States who is responsible for your treatment with the product, or provide evidence that the product is a continuation of treatment begun in a foreign country.

The condition that does the most work

Of the five, the first is the one that decides most cases, and it is easy to skim past.

It asks whether the product is for a serious condition for which effective treatment may not be available domestically, either through commercial or clinical means. Commercial means a product on the market here. Clinical means access through a trial or comparable route.

So the test is about availability in the United States, not about price, convenience, waiting time, or whether a particular seller ships faster. Where FDA-approved products for a condition are marketed in the United States, that is the condition an importer would have to be able to satisfy.

The second condition is the one that catches marketing. Where a product is being commercialized or promoted to persons residing in the United States, the page lists that as cutting against a permissive decision rather than for one. An overseas seller advertising to American buyers is describing itself out of the category.

Foreign nationals are treated differently

The page draws a line most summaries drop. A foreign national is defined there as any person who is not a citizen or permanent resident of the United States.

FDA states that it will allow foreign nationals to bring or ship a 90-day supply of drug products, and that a foreign national staying longer than 90 days may have additional medication sent.

For a shipment, the page suggests including documentation showing the medication is for the person's own use while visiting: a copy of the visa or passport, a letter from a doctor, and a copy of the prescription in English.

That is a genuinely different posture from the one applied to citizens and permanent residents, and confusing the two is how a lot of secondhand advice goes wrong.

When FDA says it will refuse

The page lists the grounds directly, and they are worth knowing because they describe what an inspector is looking for.

The product is on an FDA import alert for previous violations. The shipment appears to be intended for commercial distribution. The product appears to present a serious risk to health. The article appears to represent a health fraud. Or, for food, it was imported with inadequate prior notice.

Two of those are about the shipment rather than the substance. Quantity and packaging that read as resale, and a product flagged from prior violations, both fail without any judgment about the molecule inside.

Controlled substances are handled separately. The page states that DEA will generally make the decision on whether a controlled substance may be imported for personal use, and that where both agencies have jurisdiction they coordinate on admissibility.

The notice provision, and what it tells you about scale

Federal law contains a provision aimed specifically at individuals, and its existence says something about how often this comes up.

For a prescription drug being imported or offered for import, the Secretary may not send a warning notice to an individual who is not in the business of such importations unless conditions are met. The notice has to specify which of four determinations was made. That the drug is or appears to be adulterated, misbranded or in violation of the approval provision. That it is or appears to be forbidden or restricted in sale in the country where it was produced or exported from. That importation is or appears to violate the reimportation provision. Or that it otherwise is or appears to violate federal law.

The notice may not specify a provision that does not apply. And it has to state the reasons underlying the determination, including a brief application of the cited provision to the principal facts.

The statute defines the term too. A warning notice is a communication from the Secretary, written or otherwise, notifying a person or clearly suggesting to them that importing the drug for personal use is, or appears to be, a violation.

Read that as a procedural protection with a lesson attached. Congress wrote rules about how individuals are told they are in the wrong, which is not a thing legislatures do for situations that never arise.

How to read an overseas offer

Start with the definition rather than the price. If the seller is promoting to buyers residing in the United States, that fact is on the wrong side of FDA's own list.

Notice which claim is being made. "Approved in another country" is expressly not enough — the page says a drug approved abroad but unapproved here is illegal to import.

Notice the quantity being offered. The three-month figure in FDA's list is stated as a general limit on quantity, and a larger shipment reads as commercial distribution, which is a listed refusal ground.

Notice whether a U.S.-licensed prescriber is in the picture. Naming one, or documenting a treatment begun abroad, is one of the listed conditions rather than a formality.

And separate two questions that get merged constantly. Whether a product can lawfully cross the border is one question. Whether anyone verified what is in the vial is another, and nothing in an import decision answers it.